Show simple item record

dc.contributor.authorSalinas, Natalia Regina Antunes [UNIFESP]
dc.contributor.authorLopes, Camila Takao [UNIFESP]
dc.contributor.authorPalma, Patricia V.
dc.contributor.authorOshima, Celina Tizuko Fujiyama [UNIFESP]
dc.contributor.authorBueno, Valquiria [UNIFESP]
dc.date.accessioned2016-01-24T13:58:57Z
dc.date.available2016-01-24T13:58:57Z
dc.date.issued2009-12-01
dc.identifierhttps://dx.doi.org/10.1007/s12253-009-9152-2
dc.identifier.citationPathology & Oncology Research. Dordrecht: Springer, v. 15, n. 4, p. 549-554, 2009.
dc.identifier.issn1219-4956
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/31983
dc.description.abstractUrethane is a chemical carcinogen which causes lung tumorigenesis in mice with similarities to human adenocarcinoma (AC). the sphingosine 1-phosphate agonist FTY720 administered to mice in doses above 5 mg/kg/day has been able to prevent hepatocellular carcinoma and bladder cancer. We used BALB/c mice in urethane-induced lung cancer model to investigate the effects of a lower dose of FTY720 (1 mg/kg/day). the benefits of FTY720 were associated with the time point of the compound administration. FTY720 30 Group presented lower incidence and smaller area of lung nodules, decreased PCNA and increased Caspase-3 expressions. the findings in FTY720 0 Group (nodule multiplicity and area, PCNA expression) were similar to Urethane Group suggesting that the administration of the compound at early time point did not affect lung tumor development. FTY720 90 Group presented the biggest nodule area which was associated with increased PCNA and decreased Caspase-3 expressions. FTY720 (30 days and 90 days) administration decreased CD4 + splenocytes and blood lymphocytes which caused opposite effects in lung tumor development - impairment and improvement respectively.In conclusion, FTY720 in low dose did not provide lung tumor inhibition in mice but its administration 30 days after the chemical carcinogen (Urethane) injection was associated with impaired tumor developmenten
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.format.extent549-554
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofPathology & Oncology Research
dc.rightsAcesso restrito
dc.subjectLung canceren
dc.subjectUrethaneen
dc.subjectFTY720en
dc.subjectApoptosisen
dc.subjectProliferationen
dc.subjectCD4+T cellen
dc.titleLung Tumor Development in the Presence of Sphingosine 1-phosphate Agonist FTY720en
dc.typeArtigo
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.description.affiliationUniversidade Federal de São Paulo, Div Immunol, BR-04023900 São Paulo, Brazil
dc.description.affiliationUSP Ribeirao Preto, Sch Med, FMUSPRB, Lab Flow Cytometry, Ribeirao Preto, SP, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Div Pathol, BR-04023900 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Immunol, BR-04023900 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Pathol, BR-04023900 São Paulo, Brazil
dc.identifier.doi10.1007/s12253-009-9152-2
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000273283100002


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record